Torr S R, Nachowiak D A, Fujii S, Sobel B E
Cardiovascular Division, Washington University School of Medicine, Saint Louis, Missouri 63110.
J Am Coll Cardiol. 1992 Apr;19(5):1085-90. doi: 10.1016/0735-1097(92)90300-c.
Although initially developed to reduce the risk of bleeding, second-generation (clot-selective) thrombolytic agents have been found to induce more prompt and frequent recanalization than do nonselective, first-generation agents. To determine whether they do so in part by preserving clot-associated plasminogen, human whole blood clots formed in Chandler tubes were studied. Addition of suprapharmacologic concentrations of recombinant tissue-type plasminogen activator (rt-PA) to the media bathing mature clots led to a paradoxic impairment of clot lysis and a concomitant concentration-dependent depletion of clot-associated plasminogen (Western blot analysis). In contrast, supplementation of the plasma with plasminogen (0.27 mg/ml) led to significant conservation of both plasma and clot-associated plasminogen (p less than or equal to 0.05, n = 4), and prevented the diminution of clot lysis (p less than or equal to 0.05; n = 4). Fibrinogen degradation products did not account for the attenuation of lysis with the highest concentrations of rt-PA. In concentrations equivalent to those that were induced by the highest concentrations of rt-PA evaluated, fibrinogen degradation products potentiated rather than inhibited lysis (p less than or equal to 0.05, n = 4), probably by stimulating rt-PA activity directly. When preformed clots were incubated with plasminogen-depleted plasma plus 1,000 ng/ml rt-PA, the plasminogen content in residual clot declined (9.36 +/- 0.46 versus 12.39 +/- 0.69 ng/mg clot found in nondepleted plasma; p less than or equal to 0.05; n = 6). Furthermore, clot lysis was attenuated completely.(ABSTRACT TRUNCATED AT 250 WORDS)
尽管第二代(凝块选择性)溶栓剂最初是为降低出血风险而研发,但已发现其比非选择性的第一代溶栓剂能更迅速、更频繁地诱导血管再通。为确定它们是否部分通过保留凝块相关纤溶酶原而达到此效果,对在钱德勒管中形成的人全血凝块进行了研究。向浸泡成熟凝块的培养基中添加超药理浓度的重组组织型纤溶酶原激活剂(rt-PA),导致凝块溶解出现反常受损,同时凝块相关纤溶酶原出现浓度依赖性消耗(蛋白质印迹分析)。相反,向血浆中补充纤溶酶原(0.27毫克/毫升)可显著保留血浆和凝块相关纤溶酶原(p≤0.05,n = 4),并防止凝块溶解减少(p≤0.05;n = 4)。纤维蛋白原降解产物不能解释最高浓度rt-PA时溶解减弱的现象。在与所评估的最高浓度rt-PA诱导的浓度相当的情况下,纤维蛋白原降解产物增强而非抑制溶解(p≤0.05,n = 4),可能是通过直接刺激rt-PA活性。当将预先形成的凝块与纤溶酶原耗尽的血浆加1000纳克/毫升rt-PA一起孵育时,残留凝块中的纤溶酶原含量下降(未耗尽血浆中为12.39±0.69纳克/毫克凝块,而此处为9.36±0.46纳克/毫克凝块;p≤0.05;n = 6)。此外,凝块溶解完全减弱。(摘要截短于250字)